Q-omics provides the consensus-scored PRB3 profile across patient tissues and cancer cell-line models. PRB3 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PRB3 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, PRB3 RNA expression shows 15,073 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, LUAD, and TGCT as cancer lineages where PRB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRB3 survival associations across molecular data types. PRB3 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRB3 RNA expression–survival associations across cancer types. High PRB3 expression shows unfavorable associations in UVM, COAD and LIHC, but favorable associations in BLCA, DLBC and OV. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify UVM as the clearest survival context for PRB3 RNA expression.
This table summarizes PRB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PRB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRB3 shows lower tumor expression in HNSC and KIRC and higher tumor expression in LUAD, LUSC, BRCA and THCA. The LUAD box plot shows higher PRB3 RNA expression in tumor versus normal tissue (log2 FC = +0.758, t-test p < 0.001).
This table shows molecular features associated with PRB3 in patient tissues and cancer cell lines. In patient samples, PRB3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PRB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
